

For Immediate Release

Contact: Kim Golden
Respironics, Inc.
OEM Product Manager
203-697-6454

Respironics Introduces Philips Medical Systems' Private Labeled Flow Sensors

Murrysville, PA, April, 2006 – Respironics, Inc. (NASDAQ/NMS Symbol: RESP) is pleased to announce we have expanded our current OEM relationship with Philips Medical Systems. Philips now offers our on-airway flow sensors in addition to the CAPNOSTAT[®] 5 Mainstream and LoFlo[™] Sidestream CO₂ technologies. Under this new OEM agreement, Respironics will provide Philips with both flow and combined flow and CO₂ sensors on a private labeled basis. These sensors will be used with their new Spirometry module. The development of the Spirometry technology was a joint effort between both Respironics and Philips engineering teams. Philips plans to begin shipment of this product in April, 2006.



Spirometry technology will provide Philips' customers with on-airway respiratory mechanics measurements that include flow, pressure and volume. This data can be viewed and stored on their IntelliVue Patient Monitor. The use of the combined Flow/CO₂ sensor adapter provides Philips' customers a way to monitor both ET/CO₂ parameters from Respironics' CAPNOSTAT 5 Mainstream CO₂ Sensor and spirometry measurements simultaneously, with one cost-effective adapter.



According to Philip Nuzzo, Vice President of OEM, Respironics Critical Care, "The extension of our relationship from ET/CO₂ to flow is a validation of our ability to work closely with our customers to

CORPORATE SERVICES

1010 Murry Ridge Lane ~ Murrysville, PA 15668
T 724-387-5200 F 724-387-5010



anticipate and respond quickly to changing market needs. We are eager to explore additional business opportunities with Philips and look forward to our mutual long-term success.”

About Respironics, Inc.

Respironics is a leading developer, manufacturer and distributor of innovative products and programs that serve the global sleep and respiratory markets. Focusing on emerging market needs, the Company is committed to providing valued solutions to help improve outcomes for patients, clinicians and health care providers. Respironics markets its products in 131 countries and employs over 4,300 associates worldwide. Further information can be found on the Company’s Web site: www.respironics.com.

#

This document contains forward-looking statements, including statements relating to, among other things, developments in the healthcare industry; the success of the Company's marketing, sales, and promotion programs; future sales and acceptance of the Company's products and programs; the timing and success of new product introductions; new product development; anticipated cost savings; FDA and other regulatory requirements and enforcement actions; future results from acquisitions; acquisition integration; growth rates in foreign markets; regulations and other factors affecting operations and sales outside the United States (including potential future effects of the change in sovereignty of Hong Kong); foreign currency fluctuations; customer consolidation and concentration; increasing price competition and other competitive factors in the sale of products; interest rate fluctuations; expiration of intellectual property rights; intellectual property and related litigation; other litigation; future levels of earnings and revenues; and third party reimbursement, all of which are subject to change. Actual results may differ materially from those described in any forward-looking statements. Additional information on potential factors that could affect the Company's financial results are included in the reports filed with the SEC, including the reports on Form 10-K, 10-Q and 8-K.

© 2006 Respironics, Inc. and its affiliates

CORPORATE SERVICES
1010 Murry Ridge Lane ~ Murrysville, PA 15668
T 724-387-5200 F 724-387-5010